semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Triple-negative Breast Cancer (TNBC) Non-squamous Non-small-cell Lung Cancer (NSCLC) Estrogen Receptor-positive Breast Cancer Progesterone Receptor-positive Breast Cancer Human Epidermal Growth Factor 2 Positive Carcinoma of Breast Men or women of age ≥18 years Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 Histologically or cytologically confirmed diagnosis of solid tumor as documented in medical records Presence of metastatic disease that has progressed during or following previous treatment appropriate for the disease type Presence of radiographically measurable disease Availability of pretreatment tumor tissue Adequate hematological profile Adequate hepatic profile Adequate renal function Negative testing or adequate therapy for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C  Peripheral neuropathy of Grade >1 Presence of malignancy involving the central nervous system Presence of another major cancer Uncontrolled ongoing infection Significant cardiovascular disease or electrocardiogram (ECG) abnormalities Known diagnosis of liver cirrhosis Pregnancy or breastfeeding Major surgery within 4 weeks before the start of study therapy Prior treatment with a ROR-1-directed therapy Known tumor resistance or intolerance to a prior MMAE-containing drug
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-79.0,  Erectile Dysfunction Patients aged 18 to 79 years; 2. The diagnosis is confirmed by assessing the functional of arterial factors of panel hemodynamics (dopplerography); 3. The diagnosis is confirmed by the assessment of the IIEF-5 questionnaire 4. Patients with organic erectile dysfunction lasting at least 6 months. 5. Patients with IIEF from 6 to 22 points. 6. Patients with a permanent sexual partner for more than 3 months; 7. Sexually Active Patients. Non-inclusion 1. The use of other treatments for erectile dysfunction 2. Age under 18 and over 79 years old; 3. Anatomical deformation of the penis (angulation, cavernous fibrosis or Peyronie's disease); 4. The presence of diseases predisposing to the development of priapism (sickle cell anemia, multiple myeloma, leukemia, thrombocytopenia); 5. Running coagulation disorders; 6. The presence of tumors in the area of electrotherapy; 7. The presence of aneurysms in the propagation of radio frequency waves; 8. Angina pectoris; 9. Myocardial infarction, stroke, life-threatening arrhythmias; 10. Thrombosis, thromboembolic disease; 11. Arterial hypertension (blood pressure ≥ 170/90 mm Hg) or hypotension (blood pressure ≤ 90/50 mm Hg.); 12. The patient has a mental illness that does not allow an assessment of the effectiveness of therapy; history of alcoholism and drug addiction; 14. Active tuberculosis, chronic somatic diseases in the acute stage; 15. Condition after coronary artery bypass grafting (CABG); 16. Patient's involvement in another clinical trial in the last 3 months  Serious unwanted phenomenons associated with exposure to the apparatus. 2. Incorrect in the study. 3. A marked deterioration in the patient's condition due to an increase in the severity of the disease or the attachment of another disease. 4. The patient's appearance of non-inclusion during the study. 5. Serious deviation from the protocol. 6. The desire of the patient or his legal representative
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Alveolar Osteitis Patients who have one or more of the following in addition to severe pain, which occur within and around the socket 1-3 days after extraction and do not decrease with pain killers With a partially or completely disintegrated blood clot in the socket With exposed bone that gives a dark gray appearance With bad odor  Who does not want to be volunteer for the study Smokers During pregnancy or lactation Has a chronic systemic disorder that will affect recovery Has hematological disorder Cooperation cannot be established Previously received radiotherapy or chemotherapy Patients using oral contraceptives
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Early Childhood Development Parents who have children aged 24 months to 3 years  Parents who have children beyond the above age range
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-40.0,  Cervicogenic Headache Headache frequency of at least 1 per week for a minimum of 3 months Secondary Headache (cervical spine dysfunction) International Classification of headache Disorder: 1. Pain localized in the neck and occiput, which can spread to other areas in the head, such as forehead, orbital region, temples, vertex, or ears, usually unilateral. 2. Pain is precipitated or aggravated by specific neck movements or sustained postures. 3. At least one of the following: 1. Resistance to or limitation of passive neck movements 2. Changes in neck muscle contour, texture, tone, or response to active and passive stretching and contraction 3. Abnormal tenderness of neck musculature  Other types of headache Trigger points of upper cervical muscles Congenital conditions of cervical spine Cervical Disc herniation Fracture Cervical Artery disease Red flags of Thrust Joint Manipulation
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  His Bundle Pacing Heart Failure, Systolic AV block II or III with high expected pacing need Left ventricular ejection fraction between 40% and 55% (inclusive) Willing to participate and sign informed consent  Under 18 years old Pregnant Hypertrophic cardiomyopathy Cardiac sarcoidosis Cardiac amyloidosis Previous myocardial infarction within last 3 months Ventricular septum defect or other other left ventricular corrective surgery Congenital heart disease surgically corrected Atrial fibrillation with uncontrolled rate (if not planned for AV node ablation)
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-65.0,  Osteo Arthritis Knee Age younger than 65 years 2. Medial joint line tenderness 3. BMI less than 30 4. Varus tibiofemoral malalignment 5. Range of motion in the knee joint maintained from greater than 100 degrees of flexion to less than 15 degrees of flexion contracture 6. Osteoarthritis of the knee with any degree of cartilage damage provided that the cartilage damage in the lateral compartment not exceeding Outerbridge grade 2 7. No associated ligamentous functional instability  Age older than 65 years 2. Severe Lateral compartment osteoarthritis (Outerbridge grade 3 or 4) 3. Flexion contracture of greater than 15 degrees 4. Inflammatory arthritis, post-traumatic osteoarthritis, active knee infection
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 6.0-999.0,  Cystic Fibrosis Key Completed study drug treatment in parent study (VX19-445-116, NCT04353817), or had study drug interruption(s) in parent study but completed study visits up to the last scheduled visit of the treatment period in the parent study Key  History of study drug intolerance in the parent study Other protocol defined Inclusion/
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Tension-Type Headache diagnosis of TTH was made based on the International Classification of Headache Disorders third edition (ICHD-3 beta) (bilateral localization, pressing and tightening pain, mild-moderate intensity [≤7.0 on a visual analog scale (VAS)] no increase in pain during physical activity patients did not report any photophobia, phonophobia, vomiting or nausea, as requested by the ICHD-III diagnostic had symptoms for more than 3 months the patients had to have had at least one segmental dysfunction of the upper cervical spine in all groups (by functional and pain-provocation tests)  any other primary or secondary headache according to the ICHD-III a history of neck or head trauma (e.g., whiplash) any red flags (vertebral tumor, fracture, dislocation and infection, metabolic diseases, rheumatic and connective tissue diseases, systemic neuromuscular diseases, prolonged history of steroid use) diagnosis of any structural spinal disorders (osteoporosis, disc herniation, myelopathy, spinal stenosis, spondylolisthesis) prior surgery to the cervical spine application of other treatment methods such as physical therapy or anesthetic block to the head and neck area within the last 3 months initiation of pharmacologic prophylaxis within two months prior to randomization pregnancy
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 5.0-8.0,  Dental Pulp Cavity Primary molars with at least one of the following signs and symptoms were eligible and were included in the study badly decayed with signs of irreversible pulpitis necrosis and chronic infection such as: pain or tenderness to percussion and palpation, abscess, fistula-opening, gingival swelling, grade II and greater pathological tooth mobility, evidence of periapical/bifurcation radiolucency, All the teeth included, had physiological root resorption of less than one third of the root  Teeth showing radiographic evidence of excessive internal or external root resorption perforated pulpal floor excessive bone loss in furcation area involving the underlying tooth germ non restorable teeth were excluded from the study
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Osteonecrosis of the Jaw, Bisphosphonate Induced Osteonecrosis of the Jaw, Bisphosphonate Related Diagnosis of stage I or stage II medication related osteonecrosis of the jaws (MRONJ) according to the 2014 AAOMS position paper  Coexistence of any medical or social condition that prevents proper adherence to treatment or follow-ups (dependent patients without adequate socio-familiar support, drug addiction, severe psychiatric illness, terminal disease with life expectancy less than 3 months) Coexistence of Brown's Tumor, Paget's Disease or other bone diseases with the exception of Osteoporosis or bone metastases
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Stress Fracture of Tibia or Fibula Soldiers actively enlisted in the U.S. Army attached to basic training unit at Fort Jackson Soldiers diagnosed with a tibial diaphyseal BSI requiring convalescent leave Skeletally mature Willing to self-administer study medication Desire to continue their military commitment  History of any form of cancer Currently pregnant Paget's disease of bone Unexplained elevations of alkaline phosphatase (elevations in alkaline phosphatase may signal undiagnosed Paget's disease of bone) Pediatric and young adult patients with open epiphyses Prior external beam or implant radiation therapy involving the skeleton Recent (within the last 6 months) urolithiasis (kidney stones) Elevated serum calcium, alkaline phosphatase or uric acid Orthostatic hypotension
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Knee Arthropathy Informed consent form (signed by participant and investigator) Primary implantation Age at Between 18 and 90 years old Willing to participate in the follow-up  Missing Informed consent form Known or suspected non-compliance (e.g. drug or alcohol abuse) Enrollment of the investigator, his/her family, employees and other dependent persons Patient younger than 18 years old Revision surgery Does have a known allergy to metal in medical devices Suffers from ACL rupture Pregnancy or in the breast feeding period